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Retroviruses are obligate intracellular parasites that 
have coevolved with their hosts for millions of years. It 
is therefore not surprising that retroviruses take advan-
tage of numerous host factors during their life cycle. 
In addition to positive cellular factors that are of use to 
the virus, host cells have also evolved intracellular pro-
teins to antagonize the retroviral replication cycle. Such 
inhibitory cellular factors have been called retroviral 
restriction factors. Recently, several such restriction 
factors have been cloned, including Friend virus sus-
ceptibility factor 1, apolipoprotein B mRNA-editing 
enzyme catalytic proteins 3F and 3G, and ZAP. Here, 
we review the explosion of publications from the past 
2 years concerning TRIM5, a host factor that potently 
inhibits HIV-1 and other retroviruses.
Introduction
The first restriction factor to be described was the murine 
Friend virus susceptibility factor 1 (Fv1). It was discov-
ered as an inhibitory activity against certain strains of 
murine leukemia virus (MLV). In 1996, Fv1 was cloned 
and revealed to most closely resemble the gag gene of 
endogenous retroviruses [1]. Fv1 exists as several alleles, 
each of which possesses a unique restriction specificity. 
Mice carrying the Fv1-n allele, for example, are resis-
tant to infection by B-tropic strains of MLV but are 
susceptible to N-tropic strains (N-MLV). The block is 
also apparent in cultured cells from these mice. The viral 
determinant for this inhibition is the capsid (CA) protein, 
which forms a protective core structure around the viral 
RNA genome. The difference between a restricted and 
an unrestricted virus in the case of Fv1, for example, is 
one amino acid change in MLV CA at position 110. The 
Fv1 gene product is capable of blocking the restricted 
virus after the reverse transcription step and before inte-
gration of the viral genome, but its exact mechanism of 
action is still unknown.
Certain members of the family of apolipoprotein B 
mRNA-editing enzyme catalytic proteins (APOBEC) 
have also been shown to possess intracellular antivi-
ral activity against retroviruses. Most notably, human 
APOBEC3G and APOBEC3F show potent activity 
against HIV-1 [2–4]. The restriction factor is pack-
aged into virions in producer cells, but does not exert 
its negative influence on viral replication until the 
viral RNA is reverse transcribed in the target cell. At 
this time, APOBEC proceeds to hypermutate the viral 
genome, leading to aborted infection. Recent data 
indicate, however, that APOBEC proteins act against 
the virus by blocking accumulation of complete viral 
reverse transcripts rather than through their enzymatic 
cytidine deaminase activity [5,6]. Interestingly, HIV-1 
has evolved a strategy to prevent the deleterious actions 
of APOBEC3G: the HIV-1 Vif protein apparently binds 
to APOBEC3G in the producer cell and prevents its 
packaging into the virus by targeting it to the protea-
somal degradation pathway [7,8].
Several other retroviral restriction factors have been 
identified. Among these is ZAP, a zinc finger protein 
that inhibits cytoplasmic viral RNA accumulation, 
specifically that of MLV and several alphaviruses, 
by binding defined RNA sequences and presumably 
targeting the viral RNAs to the exosome for degrada-
tion [9,10]. Also on the growing list of antiviral cellular 
activities is a presently unknown human factor that was 
shown to trap HIV-1 particles at the plasma membrane 
in certain human cell lines, preventing viral particle 
release. It was demonstrated that the HIV-1 Vpu protein 
counteracts this factor and thus ensures proper viral 
egress [11,12]. 
TRIM5B was discovered in screens aimed at iden-
tifying the dominant inhibitory activity against HIV-1 
in rhesus macaque cells [13•] and in owl monkey cells 
[14•]. The alpha isoform of rhesus TRIM5 is a cyto-
plasmic protein that very effectively blocks HIV-1, after 
entry into the cell but before it is able to complete reverse 
transcription of its genome, and like Fv1, it was found 
to be CA-specific. Subsequently, it was found that the 
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human TRIM5B protein possesses modest activity against 
HIV-1 and that it potently inhibits certain strains of 
MLV [15•,16–19]. This review focuses on the restriction 
factor TRIM5B, its specificity, and its proposed mecha-
nism of action.
TRIM5B Background
TRIM5B is a member of the large TRIM family of pro-
teins, named for their tripartite motif consisting of RING 
finger, one or two B-boxes, and a coiled coil region [20] 
(Fig. 1). This multigene family comprises at least 68 
members, most of which are uncharacterized and have 
unknown cellular functions. Mutations in several TRIM 
family members have been implicated in diseases, such 
as familial Mediterranean fever (TRIM20), Mulibrey 
nanism (TRIM37), and Opitz syndrome (TRIM18). In 
addition to the three conserved motifs, many TRIM 
proteins contain a C-terminal B30.2 domain. TRIM5B,
which possesses such a B30.2 domain, is one splice vari-
ant of the TRIM5 gene, and the only isoform to exhibit 
restriction activity.
To date, the TRIM5B cDNAs from a large number 
of primates and cows have been cloned and tested for 
antiviral activity against retroviruses [21–25]. Interest-
ingly, a species-dependent specificity has been observed 
with respect to which virus is inhibited (Table 1). Rhesus 
TRIM5B potently restricts HIV-1, whereas the TRIM5B
orthologs from African green monkey species have a 
much broader restriction range. The African green mon-
key Cercopithecus tantalus, for example, blocks HIV-1, 
SIVmac, N-MLV, and equine infectious anemia virus. 
The human TRIM5B ortholog was found to potently 
restrict N-MLV as well as equine infectious anemia virus. 
The owl monkey, a New World monkey species, presents 
a special case: instead of TRIM5B, it expresses a gene 
fusion termed TRIMCyp, in which the B30.2 domain is 
replaced with cyclophilin A. This gene is the result of a 
retrotransposition event of a cyclophilin A cDNA into the 
owl monkey TRIM5 locus [14•,26]. The TRIMCyp pro-
tein potently restricts HIV-1, which is partially explained 
by the well-described binding of cyclophilin A to the 
HIV-1 capsid [27].
Studies by many laboratories have sought to elu-
cidate the importance of each of the four domains of 
TRIM5B (RING, B-box, coiled coil, and B30.2) for 
restriction activity (Fig. 1). Although no domain seems 
to be completely dispensable for the full inhibitory 
effect, mutants lacking the RING domain have been 
found to retain partial restriction activity [28,29]. The 
B-box, coiled coil, and B30.2 domains, however, have 
all been shown to be essential for restriction [28–30]. 
The following discusses the proposed function of each 
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Figure 1. TRIM5B schematic showing protein 
domains and their functions. RF—RING 
ﬁnger domain; v1–v4—variable regions.
Table 1. Virus speciﬁcities of TRIM5B proteins from various primate species 
TRIM5B originating species Restricted viruses
Human (Homo sapiens) N-MLV, EIAV, HIV-1 (weak)
Chimpanzee (Pan troglodytes) N-MLV
Orangutan (Pongo pygmaeus) N-MLV, SIVmac
Rhesus macaque (Macaca mulatta) HIV-1, N-MLV, SIVagm, EIAV, SIVmac (weak)
African green monkey (Cercopithecus tantalus) HIV-1, SIVmac, N-MLV, EIAV
African green monkey (Cercopithecus aethiops) HIV-1, N-MLV, EIAV, SIVagm (weak)
Owl monkey TRIMCyp (Aotus trivirgatus) HIV-1, FIV, SIVagm (weak)
Squirrel monkey (Saimiri sp) SIVmac
Spider monkey (Ateles geoffroyi) HIV-1, SIVmac, SIVagm
EIAV—equine infectious anemia virus; N-MLV—N-tropic murine leukemia virus; SIV—simian immunodeﬁciency virus. 
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the C-terminal B30.2 domain, and their roles in the 
overall mechanism of retroviral antagonism. 
The B30.2 domain
Structure
The prototype of the B30.2 domain is found in the human 
major histocompatibility complex (MHC) class I region 
comprising an exon that was initially termed B30-2 [31]. 
Independently, using computer algorithms, a closely 
related domain named SPRY was discovered in the kinase 
splA (from Dictyostelium discoideum) and in mammalian 
ryanodine receptors [32]. Sequence alignments revealed 
the SPRY domain to be contained within the slightly larger 
B30.2 domain; and in the case of TRIM5B, the B30.2 
domain is actually composed of a PRYSPRY domain (the 
PRY part constituting a 60 amino acid stretch N-terminal 
of the SPRY domain). The crystal structures of three dif-
ferent B30.2 domains have been solved recently [33–35], 
based on which the TRIM5B PRYSPRY domain can be 
modeled reasonably well. PRYSPRY forms one compact 
domain of a 13-stranded C-sandwich, containing a hydro-
phobic core and a putative ligand-binding pocket. The 
deletion of the B30.2 domain in several proteins abolishes 
interaction with their respective binding partners, which 
has lead to the assumption that B30.2 acts as a protein-
interacting module. This observation is supported by the 
evidence that the B30.2 domain in TRIM5B is essential 
for restriction activity and is the determinant for virus 
specificity [13•,15•,16–18,21,22,28,36–39]. TRIM5B
hybrid proteins, for example, that contain the human 
TRIM domains fused to the rhesus B30.2 domain are 
able to restrict HIV-1, thereby taking on the restriction 
phenotype of rhesus TRIM5B [28].
Mapping restriction specificity
One approach to determine essential regions for anti–
HIV-1 activity in the B30.2 domain of rhesus TRIM5B
is via evolutionary sequence analysis. Using this strategy, 
a 13-amino-acid patch of positively selected residues 
was identified in the SPRY domain by comparing the 
TRIM5B sequences from 17 primate genomes [37]. By 
assessing the restriction activity of chimeric rhesus-
human TRIM5B proteins, the ability to restrict HIV-1 
was narrowed down to a few amino acid residues in SPRY 
(the evolutionary hot spot, also termed v1 for variable 
region 1) [28,38]. Then, it was pinpointed more precisely 
to one specific amino acid: the mutation of residue R332 
in human TRIM5B to any uncharged amino acid results 
in anti–HIV-1 activity [40]. 
The mapping of regions important for restric-
tion of N-MLV has been more challenging. Both 
rhesus and human TRIM5B proteins are able to block 
N-MLV, though the human form is more potent, which 
makes the restriction phenotype of chimeric proteins 
difficult to interpret. Some data from chimerae never-
theless point toward the importance of two of the four 
variable, surface-exposed loops in the B30.2 domain 
(v1 and v3) in the restriction of N-MLV [41]. It was pro-
posed that the presence of negatively charged residues at 
two specific positions in the v3 region of human TRIM5B
SPRY potentiate the interaction with the positive charge 
of arginine in the MLV CA that determines N-tropism 
(R110) [41]. 
Sequence analysis revealed that the three variable 
regions in the TRIM5B SPRY domain exhibit significant 
length polymorphism from species to species [21]. The 
broad range of retroviruses restricted by African green 
monkey TRIM5B is proposed to be attributable to a 
20-amino acid insertion (sequence duplication) in the 
v1 region of the SPRY domain [21]. Another species, 
the spider monkey, was also found to restrict a wide 
variety of retroviruses, and its SPRY domain shows evi-
dence of a tandem triplication in the v3 region. Based 
on these findings, it is reasonable to assume that these 
loops of variable length impart on the B30.2 domain 
a flexible surface for interaction with diverse ligands 
(eg, capsid or other unknown structures). 
Capsid binding
Using virus chimerae, it was determined early on that 
sensitivity to TRIM5-mediated restriction is deter-
mined by the viral capsid protein. For example, rhesus 
macaque cells, which display a TRIM5B-mediated 
block to HIV-1, show much less restriction of an HIV-1 
chimera bearing a SIVmac capsid [42]. Based on this 
observation of capsid-specificity, it was reasonable to 
assume that TRIM5B directly bound to the restricted 
retroviral capsid. However, demonstrating such a direct 
interaction proved to be difficult. Conventional coim-
munoprecipitations failed, and expression of capsid 
monomers in a restrictive cell was not able to saturate 
restriction activity [43]. This led to the hypothesis that 
TRIM5B recognized a higher order structure of capsid 
multimers, possibly a hexameric unit [44], and based 
on this reasoning, two different capsid-binding assays 
were developed that recapitulate restriction specificity. 
In the first assay, detergent-stripped MLV virions were 
mixed with cell lysates containing glutathione-S-trans-
ferase–tagged human TRIM5B. Pull-down of TRIM5B
on glutathione-conjugated sepharose beads resulted 
in the cosedimentation of restricted N-tropic but not 
of unrestricted B-tropic MLV [45•]. This interaction 
was shown to be dependent on the SPRY domain. 
Unfortunately, most likely due to the relative instability 
of HIV-1 cores, this assay could not be replicated with 
rhesus TRIM5B and HIV-1 CA. 
The second approach to show TRIM5B interaction 
with capsid constitutes the reverse strategy. Here, HIV-1 
capsid complexes assembled from purified CA-NC protein 
were incubated with lysates containing TRIM5B and then 
accelerated through a sucrose cushion. The capsid pellet 
was then probed for TRIM5B. Using this assay, it was 
170 Update on AIDS
shown that the ability of TRIM5B proteins from differ-
ent species to associate with HIV-1 capsid correlates with 
their ability to restrict HIV-1 [46•]. 
In summary, the variable B30.2 domain of TRIM5B
proved to be the specificity determinant for retroviral 
restriction and associates in a complex with the viral 
capsid structure. 
The RING domain
The RING domain of TRIM5B is located at the N-
terminus of the protein and spans about 40 amino 
acids. Via cysteine residues at positions 15 and 18, it 
binds two zinc atoms, forming a “cross-brace” motif. 
RING fingers of numerous proteins (in the context of 
the tripartite motif) have been implicated in the control 
of substrate levels via their E3 ubiquitin ligase activity 
and subsequent proteasomal degradation. The RING 
finger was demonstrated to play a role in the transfer of 
ubiquitin to substrate molecules as well as to the TRIM 
proteins themselves. A biochemical interaction between 
ubiquitin-conjugating (E2) enzymes and the RING motif 
has also been shown. In the case of TRIM5, the splice 
variant TRIM5B interacts with the E2 enzyme UbcH5B 
and was found to possess auto-E3 ligase activity [47]. It 
is therefore conceivable that the TRIM5B RING finger 
possesses a similar activity, mediating the transfer of 
ubiquitin to substrate molecules and/or itself, followed 
by proteasomal targeting. 
Naturally, one proposed target of TRIM5B-medi-
ated ubiquitination is the retroviral capsid, resulting in 
its degradation by the proteasome. It was demonstrated 
for TRIM5B that a mutant lacking the RING domain 
is more stable than the wild-type protein, which is 
rapidly turned over via a proteasome-dependent mecha-
nism [48]. In addition, it was shown that although 
TRIM5B can be polyubiquitinated, the %RING mutant 
has lost this characteristic [48]. (Mono- and diubiqui-
tinated forms could still be detected, however.) This data 
suggests that the rapid turnover of TRIM5B is mediated 
via polyubiquitination of the RING domain and protea-
somal degradation.
However, the importance of the RING domain for 
TRIM5B-mediated restriction is not clear. RING finger 
mutants retain partial restriction activity [13•,18,29,49], 
demonstrating that the RING domain is not absolutely 
required for antiviral potential. It has been argued that 
the observed decrease in activity for the deletion mutant 
results from its mislocalization in the cell rather than 
from a lack of RING-domain functionality [48]. Another 
study supports the idea that ubiquitin ligase activity via 
the RING finger is not part of the restriction mechanism; 
it showed that the E1 ubiquitin-activating enzyme is not 
required for TRIM5-mediated restriction activity [49]. 
The same study did, however, acknowledge the general 
importance of the RING domain and the fact that it was 
required for full restriction activity. 
Recently, another group reported that proteasome 
inhibitors were able to counteract restriction and increase 
viral cDNA levels in the cytoplasm, even though the block 
to infectivity itself was not overcome, and nuclear viral 
DNA levels were unchanged and low [50,51]. It was pro-
posed that the TRIM5B-mediated restriction mechanism 
is composed of two pathways, one of which is mediated 
by the proteasome and can be overcome by proteasome 
inhibitors. The second mechanism, however, still prevents 
viral cDNA transport into the nucleus, so that over-
all infectivity is not affected, even if one pathway fails. 
For reasons explained earlier, the RING domain is a 
likely candidate for mediating the former pathway, via its 
E3 ligase activity. 
B-box and coiled coil domains
B-box and coiled coil domain are located C-terminal of 
the RING finger in TRIM proteins. The B-box motif 
is exclusively found in the TRIM family of proteins; it 
binds one zinc atom via conserved cysteine and histidine 
residues, but the function of B-boxes remains unknown. 
The coiled coil domain, which follows the B-box motif, is 
less conserved on the amino acid sequence level, but the 
region is always predicted to pack into the characteristic 
coiled coil formation. 
Interestingly, the TRIM5B B-box was shown to be 
essential for restriction [28,29]. Deletion of the RING/
B-box part of TRIM5B as well as mutation of the zinc-
coordinating residues in the B-box cause a complete loss 
of antiviral activity. Undoubtedly, studies are underway 
to determine the function of the TRIM5B B-box, which 
most likely occurs via interaction with an as of yet 
unknown factor. 
The coiled coil domain is thought to mediate homo- 
and hetero-interaction between TRIM proteins [20], 
which in the case of TRIM5B was demonstrated by 
the dominant negative activity of mutants lacking the 
RING/B-box domains (leaving the coiled coil/B30.2 
region intact) [29]. The activity of human TRIM5B
was also shown to be inhibited by exogenous expres-
sion of TRIMCyp or rhesus TRIM5B, presumably via 
dominant-negative coiled coil interactions [52]. In addi-
tion, the coiled coil region was shown to be required 
for self-association of TRIM5B in coimmunoprecipita-
tion experiments. Cross-linking studies furthermore 
demonstrated that TRIM5B exists as a trimer [53] and 
that the coiled coil and its C-terminal linker region are 
necessary and sufficient for trimerization [30]. The self-
association of TRIM5B is thought to have a part in the 
formation of cytoplasmic speckles that are characteristic 
of the TRIM5B intracellular localization pattern when 
overexpressed. It was demonstrated, however, that these 
cytoplasmic bodies are not required for the restriction 
activity of TRIM5B [54]. Interestingly, replacement of 
the coiled coil domain with a heterologous trimeriza-
tion domain (GCN4) recapitulated the trimerization of 
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TRIM5B but did not restore restriction activity [30]. 
This observation suggests that the coiled coil domain 
is responsible for more than oligomerization during the 
antiviral activity of TRIM5B.
Mechanism of Restriction
In the short time since its discovery in 2004, intense 
studies of the restriction factor TRIM5B have led 
to numerous publications, but its exact mechanism 
of action is still unclear. It has been established that 
TRIM5B binds to the retroviral capsid via its B30.2 
domain, and a model has been proposed in which a 
trimeric TRIM5B cluster interacts with a hexameric 
capsid subunit [30,53]. After capsid binding, it is very 
likely that a subsequent, second step is required for anti-
viral potential, whether it be an enzymatic activity of 
TRIM5B itself via its RING finger, or the recruitment 
of other factors via its B-box.
One study supports the idea that TRIM5B intervenes 
with the normal uncoating step of the viral capsid, and 
that it leads to an accelerated and therefore deleterious 
disassembly of the capsid structure, leaving the viral 
RNA unprotected. In a recent publication, the authors 
track the fate of incoming capsid in infected, restrictive 
cells. They demonstrate that after ultracentrifugation in 
the presence of TRIM5B, the particulate, intact capsid 
in the pellet is reduced, and monomeric capsid molecules 
accumulate in the supernatant [46•]. Although this study 
seems very convincing, other possible restriction mecha-
nisms include the sequestering of the incoming reverse 
transcription complex [55], or an inhibition of the 
virus via TRIM5B-mediated detrimental modification 
of the viral capsid (eg, ubiquitination or sumoylation). 
Naturally, a combination of these possibilities is also 
conceivable. In addition, restriction seems to involve 
several pathways, each resulting in the inhibition of a 
different step in the early retroviral lifecycle. Evidence 
for this multistep model is provided by proteasome 
inhibitor studies as mentioned earlier [50,51], TRIMCyp 
chimerae experiments [55], and studies using drugs that 
counteract restriction activity [56].
Conclusions
The TRIM5B-mediated restriction activity is likely to be 
a complex mechanism consisting of more than one path-
way. TRIM5B recognizes the incoming capsid structure 
via its B30.2 domain, and the domains of the tripartite 
motif take part in one or more subsequent step(s) that 
result in the inhibition of the virus. 
Recently, four studies have been conducted to deter-
mine whether polymorphisms within the human TRIM5B
gene show a correlation with susceptibility to HIV-1 
infection [57–60]. Of the several nonsynonymous single 
nucleotide polymorphisms found, none showed a correla-
tion with infectibility or progression towards AIDS. This 
does not seem surprising, since HIV-1 has been present 
in the human population for too short a period to give 
rise to detectable TRIM5B variants. However, two stud-
ies identified the importance of an allele resulting in the 
amino acid change R136Q. Although one study found 
an association of this allele with an increased susceptibil-
ity to HIV-1 infection in European Americans [57], the 
other study found a slight protective effect of R136Q in 
African Americans [60]. In addition, one nonsynonymous 
single nucleotide polymorphism that results in the amino 
acid change H43Y was shown to have decreased overall 
restriction activity (against both N-MLV and HIV-1) [58]. 
It is not clear why such a defective TRIM5B variant has 
persisted in the human population, but it is thought that a 
population bottleneck and a diminished selective pressure 
are at least partially responsible. 
Retroviral inhibition by cellular proteins is proving to 
be an important and expanding field of research. Uncover-
ing the mechanism of action of these restriction factors will 
help elucidate poorly understood stages of the retroviral life 
cycle. Most importantly, these factors have the potential 
to become clinically relevant in applications such as gene 
therapy or as new drug targets to enhance or modulate their 
endogenous antiviral activity. In the case of TRIM5B, it is 
conceivable, for example, to develop pharmacologic means 
to mask the basic residue 332 in the SPRY domain and 
therefore switch its restriction specificity towards HIV-1. 
Ongoing studies of the TRIM5 antiviral activity in many 
excellent laboratories will undoubtedly shed more light on 
this unique restriction mechanism in the future.
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